5th Genome Editing Therapeutics 2024

Start: Tuesday, December 3, 2024 9:00AM
End: Thursday, December 5, 2024 3:10PM

The 5th Genome Editing Therapeutics Summit (formerly CRISPR 2.0) is the industry's foremost meeting for spearheading the development, application, and delivery of novel gene editing technologies in the therapeutic setting. Data-driven talks, expert panel discussions, and interactive group discussions will cover the therapeutic application and drug development challenges of both:

1. More established technologies, and their associated translational, nonclinical, clinical, and strategic challenges: including novel nucleases, base, prime, and multiplex editing techniques 

2. Ground-breaking precision tools enabling small and large alterations to the genome, including epigenome editing, recombinase and transposon-based technologies, and novel delivery vehicles

Across three days, industry and academic leaders will share the latest data on the cutting-edge therapies they are progressing through development, tying in the strategies they are deploying to ensure their safety, precision, and regulatory compliance. 

This is the industry's only gene editing meeting that prioritizes drug development first, with a particular focus on robust safety packages, off-target detection, and nomination strategies; facilitating successful IND filings. Leverage actionable insights to improve the precision and safety of your technology, unlock the ability to perform small and large targeted edits, and outline a streamlined path to clinic for your lead program. 

Join us to be a part of the gene editing revolution!

Brochure: https://go.evvnt.com/2614921-2?pid=3698

Prices:
Drug Developer - All Access Pass (Conference + Workshop Day): USD 4197.00,
Drug Developer - Conference Only: USD 2999.00,
Academic - All Access Pass (Conference + Workshop Day): USD 3597.00,
Academic - Conference Only: USD 2599.00,
Solution Provider - All Access Pass (Conference + Workshop Day): USD 5097.00,
Solution Provider - Conference Only: USD 3699.00

Speakers: Andrew Anzalone, Director, Head of Prime Editing Platform, Prime Medicine, Ankit Gupta, Senior Director, Head of Gene Editing, Affini-T Therapeutics, Apiwat Wangweerawong, Director, Delivery Chemistry, Tessera Therapeutics, Barrett Nuttall, Director, AstraZeneca, Brett Staahl, Co-Founder and Vice President, External Innovation, Scribe Therapeutics, Britta Jones, Senior Scientise, Tune Therapeutics, Bryant Chica, Scientist II, Analytical Chemistry and Structural Biology, Editas Medicine, Carlo Zambonelli, Independent LNP Expert, Christina Jordan, Senior Director, IP, Tune Therapeutics, Dave Carter, Senior Director, Head of Research, Evox Therapeutics, Gabor Veres, Senior Vice President, Translational Research, Mammoth Biosciences, Jeffrey Cehelsky, Vice President - Development Operations, Intellia Therapeutics, Jeffrey Marshall, Analytical Director, mRNA and gRNA Platforms, Beam Therapeutics, Jim Wang, Vice President Regulatory Affairs, Genetic Medicine, Regeneron Pharmaceuticals, John Finn, Chief Scientific Officer, Tome Biosciences, John Murphy, Chief Scientific Officer, Arbor Biotechnologies, Jordanna Mora, Senior Director, Patient Advocacy and Centricity, Beam Therapeutics, Joseph Nabhan, Chief Scientific Officer, Vesigen Therapeutics, Kiran Musunuru, Professor of Cardiovascular Medicine and Genetics, Perelman School of Medicine, University of Pennsylvania, Laura Serwer, Senior Director, Head of Pharmacology and Toxicology, CRISPR Therapeutics, Luca Biasco, Vice President, Translational Sciences, Nvelop Therapeutics, Marco Weinberg, Senior Vice President, Head of Research, ReCode Therapeutics, Inc, Narin Ahmed, Vice President, Regulatory Science, Tessera Therapeutics, Omid Harandi, Chief Scientific Officer, Komo Biosciences, Priya Chockalingam, Vice President, Head of Clinical Bioanalytics and Translational Sciences, Beam Therapeutics, Ryan Leenay, Associate Vice President, Eli Lilly and Co., Ryo Takeuchi, Senior Director, Genome Editing, Excision BioTherapeutics, Safi Shahda, Senior Medical Director, Intellia Therapeutics, Sam Sternberg, Assistant Professor, Department of Biochemistry and Molecular Biophysics, Columbia University, Shane Wright, Associate Scientist II, Chroma Medicine, Sheryl Bowley, Director, HSC Therapies, Editas Medicine, Tobias Brambrink, Vice President, Legal and Intellectual Property, Chroma Medicine, Vivian Choi, Head of Liver, Metabolic, Lung, Eye and Ear Disease Unit, Prime Medicine